NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

Director Deals - NMC Health PLC (NMC)
BFN
Jonathan Bomford, Non Executive Director, bought 2,000 shares in the company on the 19th December 2016 at a price of 1499.64p. The Director now holds 17,000 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

21 Dec
Jefferies...
1,930.00
Buy

Full year results

FY2016 Financial Highlights
 
·        Group reported revenues increased by 38.6% to US$1,220.8m.
·        Healthcare division revenue increased by 59.2% to US$823.3m[1].
·        Distribution division revenue grew by 9.8% to US$431.9m[2]
·        Reported EBITDA increased by 63.7% to US$246.1m.
·        Reported EBITDA margin expanded by 309bps to 20.2%.
·        Net profit increased by 76.5% to US$151.4m.
·        Net profit margin increased by 267bps to 12.4%.
·        Adjusted net profit increased by 69.4% to US$165.2m.
·        Earnings per share (EPS) amounted to US$0.711 (FY 2015: US$0.443)
·        Adjusted earnings per share amounted to US$0.785 (FY 2015: US$0.506)
·        Proposed dividend pay-out ratio is maintained at 20% of profit after tax, amounting to GBP[3] 10.6 pence per share
 
FY2016 Business Highlights - A year on year (YOY) comparison
 
·        Healthcare division's patients increased by 34.5% to 4.3m.
·        Revenue per patient from healthcare services increased by 28.3% to reach US$176.3.
·        Hospital bed occupancy rates reached 74.3%, an improvement of 80bps.
·        Operational beds increased from 537 beds to 679 beds, 26.4% increase
·        Doctors' employed reached 1042, an increase of 27.5%
·        Distribution division increased its product portfolio by 9.3% to 97,600 stock keeping units (SKUs)
·        Sales and marketing personnel at the Distribution division grew 11.0% to 769

NMC Health AGM and Dividend Timetable
RNS
RNS Number : 1622D
NMC Health Plc
24 April 2017
 
NMC Health Plc - AGM and Dividend Timetable 
 
London, 24 April 2017: NMC Health Plc ("NMC" or the "Company") (LSE:NMC), the leading integrated private healthcare provider operating across the United Arab Emirates, announces circulation of its Notice of 2017 Annual General Meeting and confirms details of the timetable for payment of its 2016 final dividend.
 
The Company's 2017 Annual General Meeting will be held on Tuesday 23 May 2017, at 2:00 pm at the offices of Allen & Overy LLP, One Bishops Square, London E1 6AD. A copy of the Notice of 2016 Annual General Meeting Circular and the accompanying Form of Proxy have  been submitted to the National Storage Mechanism and are available for inspection at www.Morningstar.co.uk/uk/NSM.  In addition, the Circular is available to view on the Company's website http://www.nmchealth.com/shareholder-information.
 
Following the 2016 financial year preliminary results announcement of the Company made on 8 March 2017, in which the Board announced that it is recommending a final dividend of 10.6 pence per ordinary share, the Company hereby confirms the following timetable for payment of this dividend:
 
·     Ex-dividend date - 11 May 2017
 
·     Record date - 12 May 2017
 
·     Payment date - 2 June 2017
 
Payment of the final dividend remains subject to shareholder approval at the Company's 2017 Annual General Meeting.

Abu Dhabi regulatory and trading update
RNS
RNS Number : 8020D
NMC Health Plc
02 May 2017
 
2 May 2017
 
NMC Health plc
(the "Company" or "NMC")
 
Abu Dhabi regulatory announcement and trading update
 
 
NMC Health plc (LSE:NMC), the leading integrated healthcare provider operating across the United Arab Emirates notes the recent statements made by His Highness Sheik Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Commander of the UAE Armed Forces and subsequent confirmation by the Health Authority of Abu Dhabi ("HAAD") to NMC on 27 April 2017, regarding regulatory changes to Thiqa cardholders in Abu Dhabi, effective immediately:
 
·      The removal of the 20% co-payment on services accessed by Thiqa cardholders at private Abu Dhabi healthcare facilities;
 
·      Reduction in the co-payment for services accessed by Thiqa cardholders outside of the Emirate of Abu Dhabi from 50% to 10%; and
 
·      Removal of IVF related restrictions
 
As previously communicated, NMC's Long-term & Home Care vertical was exempt from the changes made to the co-payment on services.
 
NMC expects these changes to positively impact its entire healthcare portfolio.  In particular, NMC Royal Hospital, Al Zahra Hospital and Fakih IVF are anticipated to be key beneficiaries of the revised regulations. NMC now expects full year EBITDA to be towards the top end of the current guidance range of USD 335-350mn.

Ex divi 11 May 10.6p payment 2 June.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,180.00. Over this period, the share price is up 105.23%.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,337.00. Over this period, the share price is up 102.52%.

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 2,739.00. Over this period, the share price is up 102.07%.

Tipped by the Telegraph over the weekend.

10:50 03/10/2017
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
Jefferies International today reaffirms its hold investment rating on NMC Health PLC (LON:NMC) and raised its price target to 2810p (from 2450p). Story provided by StockMarketWire.com

6 Oct
Berenberg
4,000.00
Buy

Director Deals - NMC Health PLC (NMC)
BFN
Salma Hareb, Non Executive Director, bought 6,600 shares in the company on the 12th October 2017 at a price of 2970.98p. The Director now holds 6,600 shares representing 0.00% of the shares in issue.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Sharecast -Middle East hospital operator NMC Health was rising even higher after Deutsche Bank lifted its target price to 3,920p from 2,820p.

Acquisitions of outstanding minority interests
RNS
RNS Number : 9443A
NMC Health Plc
04 January 2018


4 January 2018

NMC Health plc
(the "Company" or "NMC")

Continued progress against group strategy

- Acquisition of minority stakes in Fakih IVF and As Salama Hospital
- Enterprise Values of both Fakih IVF and As Salama Hospital approximately the same as at the time of original acquisitions, despite substantial growth in underlying profitability
- Formal closing of Al Qadhi and Al Rashid Hospital transactions in KSA


NMC Health plc (LSE: NMC), the leading integrated healthcare provider operating across the United Arab Emirates, is pleased to announce that it has acquired the outstanding minority stakes in Fakih IVF and As Salama Hospital for a total consideration of c. USD 218mn, implying 2017 P/E multiple of just under 10x for the two assets combined. The Company also announces the completion of the previously announced Al Qadhi and Al Rashid Hospital transactions in the Kingdom of Saudi Arabia (KSA).

Acquisition of minority stakes in Fakih IVF and As Salama Hospital

NMC has acquired the outstanding 49% minority stake in Fakih IVF at approximately the same Enterprise Value as the original acquisition cost set in 2015. The acquisition is being settled in the form of cash and newly issued shares in NMC Health with a total consideration of USD 205mn (27% cash, 73% NMC shares issued, which represents c.3.5 million shares or 1.8% of NMC's current issued capital based on NMC's current share price of £29.20 ($39.42 at a GBPUSD exchange rate of 1.35 for 3 January 2018)). In addition, Dr. Michael Fakih will retain his role as a Medical Director in NMC and continue his practice as a medical doctor.

With Fakih IVF now a wholly owned subsidiary of NMC, the Company is better positioned to accelerate and expand growth globally within its fertility business. NMC will continue to expand its fertility network, from the new IVF clinics opened in UAE and Oman in 2017 and additional expansions planned in other geographies, particularly KSA, to maintain a market leading position.

As owner of the remaining 49% stake in Fakih IVF being acquired, and as a director of Fakih IVF, which is a subsidiary undertaking of NMC, Dr. Fakih is therefore deemed to be a related party to NMC for the purposes of Listing Rule 11. The transaction amounts to a smaller related party transaction as defined in Listing Rule 11.1.10.

The outstanding 30% minority stake in As Salama Hospital was acquired at the same Enterprise Value of USD 45mn which was set in 2016 with the initial 70% stake. The acquisition is being fully settled in cash.

These two acquisitions were financed from the issuance of shares to Dr. Fakih and existing cash resources from our strong and stable balance sheet which remains within our leverage guidance. In aggregate Fakih IVF and As Salama Hospital would have contributed c. USD 22mn to NMC's FY17 net income on a pro forma basis. The acquisitions became effective on 1 January 2018.

Closing of Al Qadhi and Al Rashid Hospital purchases in KSA

As announced on 25 September 2017, NMC acquired a 60% stake in Al Qadhi Hospital in Najran and a 100% stake in Al Rashid Hospital in Ha'il for an aggregate consideration of USD 40m. All formalities related to both transactions have now been completed and the contributions from both hospitals will be consolidated in NMC's results from the beginning of 2018. These facilities represent an important step ahead in NMC's drive to establish a well-developed footprint in KSA.

Prasanth Manghat, Chief Executive Officer, commented:

"In December 2017, I set out our strategy to drive the Company's next phase of growth. The transactions today fit with our commitment to increase our capacity, capabilities and geographic coverage. The acquisition of the outstanding minority stakes in Fakih IVF and As Salama Hospital represent highly value accretive transactions for NMC's shareholders. In particular, the Fakih IVF transaction provides us with an enhanced platform from which to grow our fertility business. As the second largest global IVF player, NMC remains very well positioned to be the leading consolidator in the fertility market. We will continue to seek opportunities to consolidate minority stakes in our subsidiaries, as we increase our knowledge and understanding of these businesses, where we can create further value for shareholders."

Earnings accretive acquisitions in the UAE and KSA
RNS
RNS Number : 4630C
NMC Health Plc
22 January 2018

22 January 2018

NMC Health plc
(the "Company" or "NMC")

Earnings accretive acquisitions in the UAE and Kingdom of Saudi Arabia

NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international services across 13 countries, is pleased to announce two acquisitions and the completion of new Operating and Management (O&M) contracts. These accretive transactions demonstrate further progress in-line with the Company's strategic priorities to expand capacity, capabilities and geographic reach.

- Acquisition of 70% stake in CosmeSurge and related businesses
· Transaction includes a chain of 17 operational clinics, enhancing NMC's Cosmetics services portfolio
· Purchase consideration of USD 170mn, translating into 10.6x 2018E EV/EBITDA
· High margin, double-digit growth business operating in an attractive market segment
· Expected to be earnings and margin accretive from first year of acquisition

- Increased capacity in KSA with acquisition of 80% stake in Riyadh-based Al Salam Medical Group
· Further extends NMC's foothold in KSA with a 100-bed hospital and 2 clinics in the attractive Riyadh market
· Purchase consideration translates into a blended 2018E EV/EBITDA multiple of less than 7x
· Initial consideration of c. USD 37mn payable upon closing and a deferred consideration to be paid after 1 year based on business's financial performance
· Expected to be earnings accretive from first year of acquisition

- New O&M contracts extend geographic reach into Egypt

Strengthening NMC's cosmetics and aesthetics platform

NMC has acquired a 70% stake in CosmeSurge, an industry leader in providing quality cosmetic surgery and aesthetic medicine, and related businesses, at an implied Enterprise Value of c. USD 250mn. The business is expected to deliver 2017 revenues and EBITDA of approximately USD 67mn and USD 20.5mn, respectively, representing an attractive 31% EBITDA margin. The consideration will be settled in cash and the transaction is expected to be completed during Q1 2018. Assets being acquired under the transaction include 17 operational clinics. Additionally, a 10-bed hospital and two new clinics are currently under construction in the UAE, which are scheduled for opening during H1 2018.

NMC currently provides invasive cosmetic procedures and complex surgeries and the addition of CosmeSurge will substantially enhance the Company's cosmetics and aesthetics offering. Having managed CosmeSurge and related businesses since September 2017 under an O&M contract, NMC has already identified a wide number of revenue and cost synergy opportunities. These include cross-referral of patients, reduced capex requirement from leveraging NMC's existing capacity and cost sharing of support services related to HR, IT and procurement.

CosmeSurge and related business have been acquired from Emirates Healthcare Group. Emirates Healthcare Group is majority controlled by KBBO Group, a consortium of private investors in Abu Dhabi with a portfolio of interests across a variety of sectors. The Chairman of KBBO is Khalifa Bin Butti, who is also the Executive Vice Chairman and a substantial shareholder of NMC. For the purposes of Listing Rule 11, he is a related party of NMC and the proposed transaction constitutes a related party transaction. The transaction amounts to a smaller related party transaction as defined in Listing Rule 11.1.10.

Al Salam Medical Group extends KSA footprint

NMC has acquired an 80% stake in Al Salam Medical Group, a healthcare company in Riyadh, the largest healthcare market in KSA. The transaction is expected to be completed in H1 2018 and includes the 100-bed Al Salam Medical Hospital (commissioned in Q4 2016), the Al Salam Medical Center (established in 1985) and the Ishbilia Medical Center (established in 2003).

Al Salam Medical Group's hospital and clinics focus on a number of key specialties, including cardiology and pediatrics. NMC also sees an opportunity to add substantial value to the acquired assets by introducing further specialties and sharing best practices. As such, NMC plans to add long-term care, cosmetics and IVF services, post the completion of the acquisition.

New O&M contracts expand footprint into Egypt

NMC has also signed new Operations & Management (O&M) contracts with Emirates Healthcare Group to manage its Egyptian hospitals, Dar El Fouad and As Salam International, which have a combined capacity of 860 beds. The contract will generate revenues of USD 2mn for NMC in the first year of operation. Previous guidance for 2018E revenues for the O&M vertical is therefore maintained at USD 19mn as the new contract replaces the anticipated reduction in O&M revenues due to acquisition of CosmeSurge and related businesses.

Prasanth Manghat, Chief Executive Officer, commented:

"These value accretive and earnings enhancing transactions fit well with our growth strategy. CosmeSurge represents a continuation of building NMC's capabilities and Al Salam further extends our geographic footprint in the KSA, cementing our leading position as a non-domiciled provider. We see substantial opportunities for revenue and cost synergies across both acquisitions, and the Cosmetics business in particular has the potential to be further developed into an independent business vertical at a later stage. Moreover, KSA remains a key focus market for us and despite already reaching 800 beds across existing and under-construction assets in the country, we continue to see strong growth opportunities in the Kingdom."

Completion of Fakih IVF acquisition
RNS
RNS Number : 1275D
NMC Health Plc
29 January 2018

NMC Health plc

Completion of Fakih IVF acquisition
Share Listing Application
Total Voting Rights


London, 29 January 2018: NMC Health plc (LSE: NMC), the leading United Arab Emirates private healthcare operator with international services across 13 countries announces that the acquisition of the outstanding 49% minority stake in Fakih IVF (the "Acquisition"), announced on 4 January 2018, formally completed on 28 January 2018.

As part consideration for the Acquisition, a total of 3,533,857 new ordinary shares of 10 pence each fully paid in the Company (the "Consideration Shares"), have been issued by the Company. Application has been made to the UK Listing Authority for the admission to the Official List of the Consideration Shares and to the London Stock Exchange for such shares to be admitted to trading. These shares will rank pari passu in all respects with the existing ordinary shares of the Company.

Admission of the shares to the Official List is expected to occur on 30 January 2018.

As at 29 January 2018, NMC Health plc's issued share capital consists of 207,957,709 Ordinary Shares of 10p each, with each share having one voting right attached. No shares are held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, NMC Health plc under the FCA's Disclosure and Transparency Rules.

29 Jan
Berenberg
4,000.00
Buy

Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
BFN
Barclays Capital today initiates coverage of NMC Health PLC (LON:NMC) with a overweight investment rating and price target of 4100p.

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.u

06/02/2018
BUY
Lord Clanwilliam
NED
3,000